Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

G1 Therapeutics Inc (GTHX)

G1 Therapeutics Inc (GTHX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

ONCY : 0.8310 (-6.36%)
ACLX : 75.54 (+0.44%)
ONC.TO : 1.19 (-9.16%)
GTHX : 7.15 (unch)
HALO : 46.96 (-0.76%)
SNY : 47.71 (+0.44%)
Biotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Cases

USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
GILD : 92.57 (+1.62%)
GTHX : 7.15 (unch)
AZN : 65.35 (+1.41%)
HOLX : 71.65 (+1.26%)
Biotech Innovations Paving the Way in Breast Cancer Fight

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
GILD : 92.57 (+1.62%)
GTHX : 7.15 (unch)
AZN : 65.35 (+1.41%)
HOLX : 71.65 (+1.26%)
First Prescription for COSELA® (trilaciclib) Issued in China

/PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) ("Simcere"), an innovative global biopharmaceutical company, and G1 Therapeutics, Inc., (Nasdaq:...

GTHX : 7.15 (unch)
Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

/PRNewswire/ -- USA News Group - A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of...

ONC.TO : 1.19 (-9.16%)
ONCY : 0.8310 (-6.36%)
LLY : 767.76 (+1.35%)
NEO : 16.41 (+0.06%)
ZYME : 14.14 (+4.12%)
GTHX : 7.15 (unch)
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)

EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
LLY : 767.76 (+1.35%)
NEO : 16.41 (+0.06%)
ZYME : 14.14 (+4.12%)
GTHX : 7.15 (unch)
Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

USA News Group – A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year’s...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
LLY : 767.76 (+1.35%)
NEO : 16.41 (+0.06%)
ZYME : 14.14 (+4.12%)
GTHX : 7.15 (unch)
G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript

GTHX earnings call for the period ending June 30, 2022.

GTHX : 7.15 (unch)
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights

- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue - - Completed...

GTHX : 7.15 (unch)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...

GTHX : 7.15 (unch)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar